Trial · NCT02779764
A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
NCT02779764, Phase 3, Completed, Astellas Pharma Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment. Trials, record NCT02779764. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02779764
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
- NCT number
- NCT02779764
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 164 participants, actual
- Lead sponsor
- Astellas Pharma Inc
- Conditions
- Hemodialysis Patients With Renal Anemia
- Interventions
- roxadustat
- First posted
- 2016-05-20
- Last updated
- 2024-10-31
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemoglobin (Hb) Response Rate from Week 18 to Week 24 | Week 18 to 24 | Hb response defined as average Hb within the target range |
| Secondary | Hb Response Rate from Week 46 to Week 52 | Week 46 to 52 | |
| Secondary | Average Hb from Week 18 to Week 24 | Week 18 to Week 24 | |
| Secondary | Average Hb from Week 46 to Week 52 | Week 46 to Week 52 | |
| Secondary | Change from baseline in the average Hb from Week 18 to Week 24 | Baseline and Weeks 18 to 24 | |
| Secondary | Change from baseline in the average Hb from Week 46 to Week 52 | Baseline and Weeks 46 to 52 | |
| Secondary | Proportion of participants with Hb values within the target value in each post-dosing time point | Up to Week 52 | |
| Secondary | Change from baseline in Hb to each post-dosing time point | Baseline and Up to Week 52 | |
| Secondary | Proportion of measurement points with target Hb level from Week 18 to Week 24 | Week 18 to Week 24 | |
| Secondary | Proportion of measurement points with target Hb level from Week 46 to Week 52 | Week 46 to Week 52 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38363463 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02779764
GET https://conductscience.org/api/trials/v1/NCT02779764/registered?page=2